NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles

NSF/FDA SIR：用于纳米颗粒体外安全测试的 3D 工程组织模型

• 批准号: 1237549
• 负责人: Jan Stegemann
• 金额: $ 10.53万
• 依托单位: Regents of the University of Michigan - Ann Arbor
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1237549&HistoricalAwards=false
• 关键词: NSF; FDA; SIR; 3D; Engineered

Abstract#1237549StegemannThe goal of this 1-year Scholar-in-Residence project is to develop enhanced in vitro testing methods to rigorously evaluate the safety of nanoparticles, which are increasingly being used as components of medical devices. In response to this emerging need, the U.S. Food and Drug Administration (FDA) has initiated efforts to characterize the biological effects of nanoparticles. In particular, the Office of Science and Engineering Laboratories (OSEL) in the Center for Devices and Radiological Health (CDRH) has a strong interest in nanotechnology and evaluating nanotoxicity. The PI's lab at the University of Michigan (UMich) has a longstanding interest in characterizing cell function in well defined and consistent engineered tissues composed of cells embedded directly in a 3D protein matrix, and also has been working on cell-nanoparticle interactions in these systems. Such engineered tissues mimic important aspects of the 3D environment of native tissues, and therefore have the potential to provide information on nanoparticle biocompatibility that is not available from conventional 2D cultures or animal studies.

这个为期1年的驻校学者项目的目标是开发增强的体外测试方法，以严格评估纳米颗粒的安全性，纳米颗粒越来越多地被用作医疗器械的组件。为了满足这一新的需求，美国食品和药物管理局（FDA）已经开始努力表征纳米颗粒的生物学效应。特别是，设备和放射卫生中心（CDRH）的科学和工程实验室（OSEL）办公室对纳米技术和评估纳米毒性有浓厚的兴趣。密歇根大学（UMich）的PI实验室长期以来一直对表征由直接嵌入3D蛋白质基质中的细胞组成的明确且一致的工程组织中的细胞功能感兴趣，并且一直在研究这些系统中的细胞-纳米颗粒相互作用。这种工程组织模拟天然组织的3D环境的重要方面，因此有可能提供传统2D培养或动物研究无法获得的纳米颗粒生物相容性信息。